Video

Edward Chen, MD: Amassing Data on Sarcoidosis Prevalence in Rural and Suburban Areas in the US

Author(s):

With this new decade-long cohort, Dr. Chen notes that researchers are "one step closer to a more accurate view of what sarcoidosis may be like in the United States", with has been suggested to be more prominent in African American communities.

New demographic data from a large, decade-long cohort of patients diagnosed with sarcoidosis in rural and suburban areas contributed to the limited information on how the disease affects minority groups in the United States.

The cohort data was presented at the American Thoracic Society 2020 International Conference in San Francisco during the “Emerging EPI in Obstructive and Restrictive Lung Disease” session.

In an interview with HCPLive, study author Edward Chen, MD, Pulmonary and Critical Care Medicine at Johns Hopkins University School of Medicine, spoke of the limited data suggesting a higher prevalence of sarcoidosis in African Americans.

“There's been numerous observations through the last 70 years- including observations from the military which keep a lot of good statistics- that sarcoidosis is much more commonly found amongst African Americans and particularly African Americans in the in the southeastern coastal areas of United States,” Chen said. “More recently, there have been some other some additional studies that refined this observation a little bit more than within African Americans that in particular, female African Americans seem to have a slightly higher prevalence of sarcoidosis compared to male African Americans.”

With these observations in mind, Chen and colleagues assembled a retrospective cohort of patients using the Penn State PaTH to Health data set to determine baseline demographic and clinical characteristics.

A total of 1594 patients who were diagnosed with sarcoidosis between 2011 and 2021 were included in the study, with 340 patients in the year 1 cohort, with the age of the first recorded diagnosis being less than 40 years old for 14.7% of the population.

The number of patients would steadily increase by approximately 114-177 patients per year.

The cohort was predominantly White (75.7%), with 16.8% of the total population identifying as African American and 7.5% are other. Meanwhile, ethnicity was predominantly non-Hispanic (96%), with 4% identifying as Hispanic.

“In some ways this is sort of a first step,” Chen said. “It's a subset of all the data that we may have access to. So, if we can get our search or approach refined for our smaller data set that could be applied to much larger one, and we get one step closer to a more accurate view of what sarcoidosis may be like in the United States.”

To learn more about sarcoidosis research and funding, please visit www.stopsarcoidosis.org.

Related Videos
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Kishore Iyer, MD , MBBS | Credit: Kishore Iyer on LinkedIn
Evan Dellon, MD, MPH | Credit: UNC Chapel Hill
Marlyn Mayo, MD | Credit: ACG
Kishore Iyer, MD, MBBS | Credit: Kishore Iyer on LinkedIn
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Bruce Sands, MD | Credit: Alimentiv
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
© 2024 MJH Life Sciences

All rights reserved.